Skip to main content

Table 3 Normalized absorbed doses and effective doses for [18F]PR04.MZ for all subjects and selected target organs calculated with IDAC-Dose 2.1

From: Whole-body biodistribution and radiation dosimetry of [18F]PR04.MZ: a new PET radiotracer for clinical management of patients with movement disorders

  HC-01 (M) HC-02 (M) HC-03 (M) HC-04 (F) HC-05 (F) HC-06 (F) Mean StDev CoV (%)
Organ Normalised absorbed dose (mGy/MBq)
Adrenals 1.43E−02 1.51E−02 1.40E−02 1.94E−02 1.84E−02 1.72E−02 1.64E−02 2.26E−03 13.8
Brain 1.18E−02 1.08E−02 9.72E−03 1.05E−02 1.14E−02 1.09E−02 1.09E−02 7.22E−04 6.7
Breasts 6.71E−03 7.39E−03 6.83E−03 8.48E−03 8.74E−03 9.12E−03 7.88E−03 1.03E−03 13.1
Colon 1.69E−02 1.87E−02 1.56E−02 1.95E−02 1.73E−02 1.67E−02 1.75E−02 1.42E−03 8.1
Cortical bone surface 2.40E−02 2.42E−02 2.59E−02 2.81E−02 2.51E−02 3.04E−02 2.63E−02 2.50E−03 9.5
Eye lenses 5.58E−03 6.18E−03 5.91E−03 7.03E−03 7.12E−03 7.81E−03 6.61E−03 8.50E−04 12.9
Gallbladder wall 3.30E−02 3.65E−02 3.47E−02 3.83E−02 3.01E−02 2.04E−02a 3.22E−02 6.42E−03 20.0
Heart wall 1.16E−02 1.15E−02 1.08E−02 1.23E−02 1.12E−02 1.18E−02 1.15E−02 5.13E−04 4.4
Kidneys 2.12E−02 2.22E−02 1.98E−02 2.25E−02 2.25E−02 2.23E−02 2.18E−02 1.07E−03 4.9
Left colon wall 1.83E−02 1.99E−02 1.60E−02 2.16E−02 1.87E−02 1.83E−02 1.88E−02 1.87E−03 9.9
Liver 2.18E−02 2.23E−02 2.16E−02 2.48E−02 2.42E−02 2.01E−02 2.25E−02 1.75E−03 7.8
Lungs 1.50E−02 1.32E−02 1.37E−02 1.50E−02 1.58E−02 1.74E−02 1.50E−02 1.51E−03 10.0
Muscle 7.25E−03 8.40E−03 7.87E−03 1.01E−02 1.02E−02 1.08E−02 9.10E−03 1.45E−03 15.9
Oesophagus wall 1.10E−02 1.15E−02 1.10E−02 1.25E−02 1.25E−02 1.32E−02 1.20E−02 9.14E−04 7.6
Ovaries 0.00E + 00 0.00E + 00 0.00E + 00 1.56E−02 1.58E−02 1.43E−02 1.52E−02 8.14E−04 5.3
Pancreas 2.59E−02 1.78E−02 1.76E−02 2.16E−02 1.91E−02 1.74E−02 1.99E−02 3.33E−03 16.7
Pituitary gland 9.50E−03 9.72E−03 9.09E−03 1.24E−02 1.24E−02 1.35E−02 1.11E−02 1.88E−03 16.9
Prostate 1.41E−02 1.69E−02 1.62E−02 0.00E + 00 0.00E + 00 0.00E + 00 1.57E−02 1.46E−03 9.3
Rectosigmoid colon wall 1.08E−02 1.28E−02 1.22E−02 1.44E−02 1.45E−02 1.27E−02 1.29E−02 1.40E−03 10.8
Red marrow 2.57E−02 2.61E−02 2.46E−02 2.69E−02 2.72E−02 2.86E−02 2.65E−02 1.38E−03 5.2
Right colon wall 1.84E−02 2.05E−02 1.70E−02 1.99E−02 1.74E−02 1.72E−02 1.84E−02 1.49E−03 8.1
SI wall 1.11E−02 1.23E−02 1.10E−02 1.51E−02 1.43E−02 1.34E−02 1.29E−02 1.69E−03 13.1
Skin 5.08E−03 5.95E−03 5.53E−03 6.88E−03 7.05E−03 7.44E−03 6.32E−03 9.38E−04 14.8
Spleen 1.17E−02 1.15E−02 1.30E−02 1.17E−02 1.08E−02 1.29E−02 1.19E−02 8.55E−04 7.2
Stomach wall 2.45E−02 1.80E−02 1.45E−02 2.26E−02 1.62E−02 1.26E−02 1.81E−02 4.65E−03 25.7
Testes 5.88E−03 7.22E−03 6.63E−03 0.00E + 00 0.00E + 00 0.00E + 00 6.58E−03 6.72E−04 10.2
Thymus 9.25E−03 9.89E−03 9.47E−03 1.11E−02 1.14E−02 1.23E−02 1.06E−02 1.21E−03 11.5
Thyroid 7.81E−03 8.64E−03 8.21E−03 9.66E−03 9.94E−03 1.08E−02 9.18E−03 1.14E−03 12.5
Ureters 1.28E−02 1.45E−02 1.33E−02 1.78E−02 1.72E−02 1.66E−02 1.54E−02 2.12E−03 13.8
Urinary bladder wall 2.44E−02 2.95E−02 2.89E−02 3.07E−02 3.04E−02 1.92E−02 2.72E−02 4.53E−03 16.7
Uterus/Cervix 0.00E + 00 0.00E + 00 0.00E + 00 1.91E−02 1.92E−02 1.54E−02 1.79E−02 2.17E−03 12.1
ICRP Standard Normalised effective dose (mSv/MBq)
ED ICRP 60 1.75E−02 1.73E−02 1.61E−02 1.65E−02 1.54E−02 1.47E−02 1.63E−02 1.08E−03 6.7
ED ICRP 103 1.59E−02 1.60E−02 1.47E−02 1.91E−02 1.75E−02 1.64E−02 1.66E−02 1.52E−03 9.2
  1. aSubject underwent cholecystectomy prior to inclusion